#USA #Boston #Clinical Trials #PhaseV #Enrollment Lab

PhaseV Introduces Its AI-Powered Enrollment Lab

PhaseV, an innovative force in the realm of clinical development, has unveiled its latest high-tech solution, the AI-Powered Enrollment Lab, during the 17th Annual SCOPE Summit. This cutting-edge addition to the PhaseV ClinOps platform is set to transform the method of planning clinical trials by replacing theoretical models with data-driven insights. Through the use of real-world Electronic Health Records (EHR), the Enrollment Lab enables sponsors to quantify a study's actual enrollment potential before they finalize their protocols.

What is the Enrollment Lab?

The Enrollment Lab aims to change how clinical trials are designed by leveraging artificial intelligence to analyze patient eligibility criteria in context with existing trial competitions. By understanding these dynamics earlier in the development process, clinical trial teams can avoid potential pitfalls related to enrollment constraints and assess various scenario outcomes.

Raviv Pryluk, CEO and Co-founder of PhaseV, emphasized the necessity of using real-world data: "With the AI Enrollment Lab, we replace theoretical planning with evidence-based certainty much earlier in the development lifecycle." This statement highlights a fundamental shift in how trials can be set up, allowing for adjustments that are informed by actual patient demographics rather than assumptions.

Benefits of AI Integration in Clinical Trials

The AI functionality empowers clinical trial teams to view the potential impacts of various eligibility criteria modifications on both patient populations and competitors. This ensures a more grounded approach in determining feasible patient recruitment strategies. The Enrollment Lab provides study teams with the tools to evaluate how different inclusion and exclusion factors affect patient volume, which can lead to optimizing trial designs that are more effective and realistic.

Moreover, this innovative lab opens up opportunities to identify unchartered geographical areas and uncover high-opportunity patient segments that previously went unnoticed. Elad Berkman, CTO and Co-founder, mentioned the Enrollment Lab as a "significant technical step forward" that transforms protocol design choices into actionable insights regarding real patient access, streamlining the process of executing clinical trials with greater accuracy.

Early Adoption in Study Planning

Strategically implemented at the onset of the study planning stage, the Enrollment Lab clarifies what is realistically attainable prior to identifying clinical sites. By showcasing where eligible patients are located while considering eligibility constraints and competitive access, the Enrollment Lab plays a crucial role in informing protocol design and geographic approaches. This not only helps in prioritizing investigator sites but aligns them with a feasible enrollment plan, setting a solid foundation for subsequent phases of the clinical trial process.

PhaseV's commitment to enhancing clinical trial efficacy is evident as they showcase the Enrollment Lab during the SCOPE Summit, inviting attendees to experience its revolutionary features firsthand. For those interested in seeing the Enrollment Lab in action, demos are available upon request.

About PhaseV

Based in Boston, PhaseV is at the forefront of redefining clinical development through its integrated AI/ML platform. Their comprehensive solutions—ranging from ClinOps and Trial optimization to Portfolio and Response Optimizers—are designed to assist biopharma sponsors and Contract Research Organizations (CROs) in selecting the most suitable assets, patient populations, and therapeutic indications. These advanced AI-driven tools have been shown to deliver exceptional returns on investment for over 40 leading pharmaceutical and biotech clients, reducing overall trial costs by nearly 50% while increasing the chances of success by over 30%.

For more information, visit www.PhaseVTrials.com and stay updated by following them on LinkedIn.